Singapore: In a move to promote openness, transparency and collaboration in research and development, multinational pharmaceutical company GlaxoSmithKline (GSK) has thrown open its TB compound library.
GSK scientists have screened the company's entire pharmaceutical compound library of more than two million compounds for any that may inhibit tuberculosis (TB) bacteria and will publish in a scientific journal the results of this process - about 200 promising hits that could act as new starting points for the discovery of new medicines for TB. This is the first time a pharmaceutical company will have made public its own proprietary compounds which have demonstrated signs of activity against TB.
To read the original article: GSK makes its TB compound library freely available - BioSpectrum Asia
